Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Intrinsic Value
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental bi... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ZNTL.
Zentalis Pharmaceuticals Inc's market capitalization is 786.2m USD.
ZNTL stock price is 11.13 USD.
ZNTL.
ZNTL. Open DCF Valuation
ZNTL. Open Relative Valuation
ZNTL has upside potential of 215% compared to the average analyst price target.
Open Wall St Estimates
ZNTL has negative Free Cash Flow for the last twelve months.
ZNTL's Altman Z-Score is equal to 2.41.
ZNTL has negative Operating Income for the last twelve months.
ZNTL has negative Net Income for the last twelve months.
ZNTL's ROE (Return on Equity) has significantly increased in the last 3 years from -92% to -64%, and is approaching profitability.
ZNTL's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -795% to -411%, and is approaching profitability.
ZNTL's ROE (Return on Equity) for the past 12 months is negative and is equal to -64%.
ZNTL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -411%.
ZNTL has negative three-year average ROE (Return on Equity): -60%. The company is not efficient at transforming stockholders' equity into net income.
ZNTL has negative three-year average ROIC (Return on Invested Capital): -426%. The company is not efficient at using invested capital to generate operating income.
ZNTL's short-term assets (528m USD) exceed its short-term liabilties (59m USD).
ZNTL's long-term assets (586m USD) exceed its long-term liabilties (104m USD).
ZNTL's D/E (Debt to Equity) is very low and is equal to 0.
Fundamental Analysis
Zentalis Pharmaceuticals Inc
Balance Sheet Decomposition
Zentalis Pharmaceuticals Inc
| Current Assets | 528.3m |
| Cash & Short-Term Investments | 516.6m |
| Receivables | 1.9m |
| Other Current Assets | 9.7m |
| Non-Current Assets | 57.5m |
| PP&E | 42.6m |
| Intangibles | 3.7m |
| Other Non-Current Assets | 11.1m |
| Current Liabilities | 58.9m |
| Accounts Payable | 14.3m |
| Accrued Liabilities | 44m |
| Other Current Liabilities | 654k |
| Non-Current Liabilities | 45m |
| Other Non-Current Liabilities | 45m |
Earnings Waterfall
Zentalis Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-299.5m
USD
|
|
Operating Income
|
-299.5m
USD
|
|
Other Expenses
|
7.3m
USD
|
|
Net Income
|
-292.2m
USD
|
Free Cash Flow Analysis
Zentalis Pharmaceuticals Inc
ZNTL Profitability Score
Profitability Due Diligence
Zentalis Pharmaceuticals Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Zentalis Pharmaceuticals Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ZNTL Solvency Score
Solvency Due Diligence
Zentalis Pharmaceuticals Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Zentalis Pharmaceuticals Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ZNTL
is 35.09 USD
with a low forecast of 15.15 USD and a high forecast of 52.5 USD.
Ownership
ZNTL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ZNTL Price
Zentalis Pharmaceuticals Inc
| Average Annual Return | 35.4% |
| Standard Deviation of Annual Returns | 102.06% |
| Max Drawdown | -88% |
| Market Capitalization | 786.2m USD |
| Shares Outstanding | 70 960 200 |
| Percentage of Shares Shorted | 29.76% |
Company Profile
Zentalis Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
You don't have any saved screeners yet
